A model-based pharmacokinetic assessment of drug-drug interaction between tacrolimus and nirmatrelvir/ritonavir in a kidney transplant patient with COVID-19

In conclusion, nirmatrelvir/ritonavir greatly increases tacrolimus concentrations by not only reducing clearance, but also increasing bioavailability. Interactions between nirmatrelvir/ritonavir and low-bioavailability drugs which are substrates for CYP3A and P-glycoprotein, such as tacrolimus, are harmful, and concomitant use of these medicines should be avoided.PMID:37924724 | DOI:10.1016/j.dmpk.2023.100529

Source: Drug Metabolism and Pharmacokinetics - November 4, 2023 Category: Drugs & Pharmacology Authors: Takeshi Tomida Kotaro Itohara Kazuhiro Yamamoto Takeshi Kimura Kohei Fujita Atsushi Uda Yumi Kitahiro Naoki Yokoyama Yoji Hyodo Tomohiro Omura Ikuko Yano Source Type: research